Skip to main content

Boston Scientific Corporation (BSX) Stock

Boston Scientific Corporation Stock Details, Movements and Public Alerts

Boston Scientific Corporation (BSX): The $100 Billion Medtech Pioneer Leading Cardiovascular Innovation

Under CEO Mike Mahoney's leadership since 2012, Boston Scientific has evolved from a struggling medtech company into one of the industry's most innovative growth stories. The company's flagship Watchman device for stroke prevention and its industry-leading FARAPULSE pulsed field ablation system have revolutionized cardiac care. With over 45,000 employees serving physicians in more than 130 countries, Boston Scientific generates $14+ billion in annual revenue across cardiovascular, rhythm management, and MedSurg divisions. The company's aggressive M&A strategy—including the $3.7 billion Axonics acquisition in 2024—combined with a robust pipeline of FDA-approved innovations, positions it as a top-tier growth investment in the medical device sector. For investors seeking exposure to aging demographics and breakthrough cardiac technologies, BSX represents a compelling blend of innovation, execution, and market leadership.

52-Week Range

$109.50 - $83.38

-8.13% from high · +20.65% from low

Avg Daily Volume

123,351

Latest volume

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

58.46

Above market average

Forward P/E

29.24

Earnings expected to grow

PEG Ratio

1.51

Reasonably valued

Price to Book

6.49

EV/EBITDA

33.79

EPS (TTM)

$1.66

Price to Sales

7.87

Beta

0.66

Less volatile than market

How is BSX valued relative to its earnings and growth?
Boston Scientific Corporation trades at a P/E ratio of 58.46, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 29.24 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 1.51 indicates reasonable value when growth is considered.
What is BSX's risk profile compared to the market?
With a beta of 0.66, Boston Scientific Corporation is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 6.49 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

13.60%

Operating Margin

18.60%

EBITDA

$4.71B

Return on Equity

11.60%

Return on Assets

5.39%

Revenue Growth (YoY)

22.80%

Earnings Growth (YoY)

140.90%

How profitable and efficient is BSX's business model?
Boston Scientific Corporation achieves a profit margin of 13.60%, meaning it retains $13.60 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 18.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 11.60% and ROA at 5.39%, the company achieves moderate returns on invested capital.
What are BSX's recent growth trends?
Boston Scientific Corporation's revenue grew by 22.80% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings increased by 140.90% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against MEDICAL DEVICES industry averages for proper context.

Company Size & Market

Market Cap

$145.5B

Revenue (TTM)

$18.49B

Revenue/Share (TTM)

$12.53

Shares Outstanding

1.48B

Book Value/Share

$15.14

Asset Type

Common Stock

What is BSX's market capitalization and position?
Boston Scientific Corporation has a market capitalization of $145.5B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 1.48B shares outstanding, the company's ownership is widely distributed. As a major player in the MEDICAL DEVICES industry, it competes with other firms in this sector.
How does BSX's price compare to its book value?
Boston Scientific Corporation's book value per share is $15.14, while the current stock price is $100.60, resulting in a price-to-book (P/B) ratio of 6.64. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$124.51

23.77% upside potential

Analyst Recommendations

Strong Buy

6

Buy

24

Hold

3

Sell

0

Strong Sell

0

How reliable are analyst predictions for BSX?
33 analysts cover BSX with 91% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $124.51 implies 23.8% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on BSX?
Current analyst recommendations:6 Strong Buy, 24 Buy, 3 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 1, 2025, 05:20 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for BSX and get notified when the price changes.

Boston Scientific Corporation (BSX) Stock Analysis 2025: Complete Investment Guide

When Mike Mahoney became CEO of Boston Scientific in 2012, the company faced stagnant growth, quality issues, and fierce competition from Medtronic and Abbott. Fast forward to 2025, and BSX has become Wall Street's darling medtech stock—delivering 400%+ returns over the past five years. The secret? A relentless focus on innovation in electrophysiology and structural heart disease, combined with strategic acquisitions that expanded its addressable market from $15 billion to $35+ billion. For investors, Boston Scientific represents the rare combination of market leadership, technological differentiation, and sustained double-digit organic growth.

Business Model & Competitive Moat

Boston Scientific operates across three core divisions: Cardiovascular (52% of revenue), Rhythm & Neuro (28%), and MedSurg (20%). The company's moat stems from three competitive advantages:

  • •Technological Leadership: FARAPULSE pulsed field ablation represents a generational leap in treating atrial fibrillation, with 70% faster procedure times and superior safety vs. traditional thermal ablation
  • •Clinical Evidence & Physician Relationships: Over 50,000 physicians trained on BSX platforms, creating switching costs and recurring revenue streams
  • •Regulatory Expertise: Industry-leading FDA approval rates with 15+ product approvals in 2024 alone, including breakthrough designations for Watchman FLX Pro

The company's installed base of cardiac devices generates recurring revenue through replacement cycles every 7-10 years, creating predictable cash flows. Mike Mahoney's strategy focuses on 'big bet' innovations rather than incremental improvements—a philosophy that has driven market share gains in electrophysiology from 15% (2018) to 35%+ (2025).

Financial Performance

Boston Scientific's financial trajectory reflects operational excellence under Mahoney's leadership:

Metric20202024EGrowth
Revenue$10.7B$14.8B+38%
Operating Margin18.2%24.5%+630 bps
EPS$1.03$2.35+128%
Free Cash Flow$1.8B$3.2B+78%
  • •Revenue Mix: High-margin cardiovascular segment growing 13% annually, offsetting slower MedSurg growth (6%)
  • •International Expansion: Emerging markets contributing 15% of revenue with 18% growth rates
  • •R&D Investment: 11% of revenue ($1.6B+) funding next-generation platforms like transcatheter mitral valve replacement

Growth Catalysts

  • •FARAPULSE Adoption: $2B+ revenue opportunity by 2027 as global rollout accelerates across 40+ countries
  • •Watchman Expansion: Stroke prevention device targeting $5B market with only 15% penetration; next-gen FLX Pro launching 2025
  • •Structural Heart Pipeline: Transcatheter mitral and tricuspid valve programs entering pivotal trials (2026 FDA approval expected)
  • •M&A Integration: Axonics acquisition ($3.7B) adds high-growth sacral neuromodulation franchise with 25% revenue growth
  • •China Recovery: VBP pricing stabilizing with volume growth offsetting margin pressure in $1.5B China business

Risks & Challenges

  • •Competitive Pressure: Abbott's QDOT Micro and Medtronic's Affera system targeting FARAPULSE's market share in electrophysiology
  • •Regulatory Risk: Structural heart programs face uncertain FDA timelines with historical device approval challenges
  • •Valuation Premium: 29x forward P/E leaves limited margin for execution missteps or slower-than-expected FARAPULSE uptake
  • •Recall History: Past quality issues (2010 defibrillator recall) create ongoing FDA scrutiny and reputational risk
  • •Currency Headwinds: 45% international revenue exposure amplifies dollar strength impact on reported earnings

Competitive Landscape

Boston Scientific competes in a $60 billion global medical device market dominated by three titans:

CompanyMarket CapRevenue GrowthKey Strength
Boston Scientific$102B12%Innovation velocity
Medtronic$105B5%Diversification
Abbott$180B9%FreeStyle Libre
Edwards Lifesciences$48B8%TAVR leadership

BSX differentiates through R&D intensity (11% of revenue vs. 7-8% peers) and aggressive early-stage technology acquisitions. While Medtronic struggles with legacy product portfolios and Abbott focuses on diabetes tech, Boston Scientific capitalizes with focused bets on high-growth cardiac subspecialties.

Who Is This Stock Suitable For?

Perfect For

  • ✓Growth investors seeking exposure to aging demographics and cardiac care innovation
  • ✓Healthcare sector investors willing to pay premium valuations for execution and pipeline quality
  • ✓Long-term holders (5+ years) who can weather regulatory approval cycles and market volatility

Less Suitable For

  • ✗Value investors seeking discounted entry points (stock rarely trades below 25x forward earnings)
  • ✗Income investors—no dividend with management prioritizing M&A and R&D reinvestment
  • ✗Risk-averse investors concerned about device recall history or clinical trial binary outcomes

Investment Thesis

Boston Scientific earns a BUY rating for growth-focused investors. The company's 12% organic revenue growth and 200+ basis points of annual margin expansion create a powerful earnings compounding story. Mike Mahoney's track record—transforming a $20B market cap company (2012) into a $100B+ leader—demonstrates execution capability. The FARAPULSE platform alone justifies current valuation, with $2B+ peak sales potential representing 15% revenue growth by 2027. Key risks center on competitive threats from Abbott and Medtronic, plus binary outcomes in structural heart trials. However, the combination of market leadership in electrophysiology, robust free cash flow ($3.2B+), and 40+ products in late-stage development provides multiple pathways to sustained outperformance.

At 29x forward P/E, Boston Scientific trades in line with high-growth medtech peers but below software multiples despite comparable growth rates. The stock's premium reflects quality—BSX has consistently exceeded guidance over 15+ consecutive quarters. Investors should accumulate on any pullback below $80 (27x forward earnings) while maintaining conviction through regulatory approval cycles.

Conclusion

For investors seeking exposure to secular healthcare trends with a proven management team, Boston Scientific offers compelling risk-reward at current levels. The combination of innovation leadership, financial discipline, and demographic tailwinds supports a long-term holding through normal market volatility. Accumulate on weakness with a 3-5 year investment horizon.
Bull Case
$105 (20% upside) - FARAPULSE exceeds $2.5B sales by 2027, structural heart trials succeed, margins reach 27%
Base Case
$92 (5% upside) - 12% revenue growth continues, margins expand to 25%, competitive landscape remains stable
Bear Case
$72 (18% downside) - Competitive losses in electrophysiology, structural heart delays, FDA recall or clinical trial failure

Stay Ahead of the Market with Boston Scientific Corporation Alerts

Set up price alerts for Boston Scientific Corporation and get notified instantly when the price hits your target. Never miss an important price movement again.